NorthWest Biotherapeutics Inc (NWBO)

[abc1212]

Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence

https://link.springer.com/article/10.1186/s13045-022-01298-0#Tab2

Liau et al. published a Phase III trial of DCVax-L, an autologous tumor lysate-pulsed DC vaccine, in 331 patients. Patients were randomized to either TMZ and placebo or TMZ and DCVax-L, with crossover to the vaccine cohort permitted upon recurrence. In the intention to treat analysis, mOS was 23.1 months postoperatively. In subgroup analyses, methylated MGMT (O6-methylguanine-DNA-methyltransferase) promotor patients had an mOS of 34.7 months, while MGMT-unmethylated patients had mOS of 19.8 months, and 186 patients had followed up?>?36 months postoperatively. [139]. While these studies show mixed results (with this statement they include other trials mentioned earlier), the capability of the vaccine to be customized to the patient’s own tumor cannot be understated. When this technology progresses, this may offer an avenue for personalized therapy.

DC vaccines remain promising because of their very low side effect profile as currently published and their high specificity to the antigens within the GBM. Their ability to be customized to the patient in a safe and efficient manner offers precision unparalleled by many other treatment types. Additionally, they can be combined with almost any other therapeutic drug to achieve many different goals. Their expansion into the sphere of oncology will be robust, and they will be offered for many different pathologies in the near future.













.